Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone monotherapy for bipolar I depression
2013-003038-34Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder and bipolar disorder (BD) comparing Lurasidone monotherapy with Placebo (2 arms). Primary endpoint: Change from baseline in MADRS total score at Week 6. Started May 2015; status: completed.
02
Drugs
lurasidone
03
Conditions
bipolar I disorderbipolar disorder (BD)
Beyond the preview
Go deeper on 2013-003038-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003038-34.